Headache Relief Research Articles

Frequency of Headaches in Macromastia Patients and Relief After Reduction Mammoplasty.

Several studies have reported that neck, back, and shoulder pain can be reduced after macromastia. However, only 1 study has specifically investigated the relation between macromastia and headaches. This study aimed to determine the frequency of headaches in patients with macromastia by examining a sample from our clinic and to determine whether the patients experienced headache relief following breast reduction surgery. One hundred patients, out of 456 patients who met the criteria, were contacted by telephone and administered a questionnaire. Statistical analysis was performed with SPSS version 17.0. Normal distribution of the variables was examined by histograms and Kolmogorov-Smirnov tests. Pearson's chi-square and Fisher's exact tests were used to compare groups. The Mann-Whitney U test was used to evaluate nonparametric variables between the patients who has 1500 grams or less breast tissue removed and the patients more than 1500 grams breast tissue removed. The incidence of headaches in patients with macromastia was found to be 29%. Among the patients with headaches, 65.52% reported relief after surgery. The relief rate for headaches was found to be associated with the amount of tissue removed. The incidence of headaches increased in patients with macromastia compared with the general population, and patients reported headache relief after surgery. In addition, as the amount of tissue removal increased, the relief rate for headaches after surgery also increased. Although additional studies are essential, preoperative headaches should be evaluated in breast reduction patients, and the removal of larger amounts of breast tissue should be considered among patients who report headaches.

Contact Point Headache- Evaluation and Surgical Treatment

Introduction: Contact point headache must be considered in patients who have no other identifiable cause of their headache. Otorhinolaryngologist should carefully evaluate the patients with headache for any possible contact points within the nasal cavity. Aim: To identify the incidence of contact point headache and evaluate the results of surgery in patients suffering from contact point headache. Materials and Methods: This longitudinal study was carried out from October 2005 to March 2006 in the Department of Otorhinolaryngology, Safdarjung Hospital, New Delhi, India. In this study 20 patients, presented to Ear, Nose and Throat Outpatient Department (ENT OPD) with complaints of headache, were screened for contact point headache. Detailed history were taken, diagnostic nasal endoscopy and computed tomography scan of nose and paranasal sinuses was done to demonstrate a contact point. A 4% xylocaine with adrenaline (1:100000 conc.) cotton swab pack was placed between the intranasal contact point for five minutes and relief of headache was noted, if any. A total of 18 septoplasties and two Middle Turbinate (MT) lateralisations were performed. Patients were followed-up for a period of four months postoperatively. Results: In the study, incidence of contact point headache was 13%. The headache duration ranged from 18-180 months, average duration being about 45.8 months. Postoperatively, 15 (75%) had total relief of their headache in terms of frequency, intensity and duration, 3 (15%) patients had significant relief and 2 (10%) had no relief of headache. Conclusion: The results for surgical treatment of contact point headache in the study have been rewarding, therefore surgery should be considered in patients whose headache are refractory to all forms of medication, with intranasal contact point, as an intranasal contact point may be the trigger factor for headache.

Contact Point Headache- Evaluation and Surgical Treatment

Introduction: Contact point headache must be considered in patients who have no other identifiable cause of their headache. Otorhinolaryngologist should carefully evaluate the patients with headache for any possible contact points within the nasal cavity. Aim: To identify the incidence of contact point headache and evaluate the results of surgery in patients suffering from contact point headache. Materials and Methods: This longitudinal study was carried out from October 2005 to March 2006 in the Department of Otorhinolaryngology, Safdarjung Hospital, New Delhi, India. In this study 20 patients, presented to Ear, Nose and Throat Outpatient Department (ENT OPD) with complaints of headache, were screened for contact point headache. Detailed history were taken, diagnostic nasal endoscopy and computed tomography scan of nose and paranasal sinuses was done to demonstrate a contact point. A 4% xylocaine with adrenaline (1:100000 conc.) cotton swab pack was placed between the intranasal contact point for five minutes and relief of headache was noted, if any. A total of 18 septoplasties and two Middle Turbinate (MT) lateralisations were performed. Patients were followed-up for a period of four months postoperatively. Results: In the study, incidence of contact point headache was 13%. The headache duration ranged from 18-180 months, average duration being about 45.8 months. Postoperatively, 15 (75%) had total relief of their headache in terms of frequency, intensity and duration, 3 (15%) patients had significant relief and 2 (10%) had no relief of headache. Conclusion: The results for surgical treatment of contact point headache in the study have been rewarding, therefore surgery should be considered in patients whose headache are refractory to all forms of medication, with intranasal contact point, as an intranasal contact point may be the trigger factor for headache.

Medication Overuse Headache.

Medication overuse headache (MOH) is one of the highly disabling headache disorder and affects about 1% of the population of the world. It is associated with the development of headache for 15 days or more, with consumption of acute symptomatic medications for 10-15 days (depending on the class of drug, like, simple analgesics, triptans, and opioids) in a month, used for relief of headache for three or more months, in a known patient of primary headache disorder. The aim of this study was to review the topic of MOH and present the details of this disorder with an emphasis on recent updates in the field of pathophysiology and treatment. Literature search was performed in the PubMed/MEDLINE and Cochrane database with appropriate keywords and relevant full-text articles were reviewed for writing this article. Over the years, the concept of MOH has evolved, although the exact pathophysiology is still being explored. In a susceptible individual interplay of genetics, change in pain pathways, changes in areas of the brain associated with the perception of pain, and changes in the neurotransmitters have been implicated. It has to be differentiated from other secondary chronic daily headache disorders, by a careful history, targeted examination, details of intake of medications. Treatment predominantly involves patient education, removal of the offending agent, and initiation of prophylactic medications for primary headache disorder in the outpatient or inpatient services. MOH is a secondary headache disorder, which should be considered in any chronic headache patient. There are various pathophysiological mechanisms attributed to its development. Management includes educating the patients about the disorder, detoxification, and prophylactic therapy.

THE EFFECTIVENESS OF MYOFASCIAL RELEASE IN THE CERVICAL REGION FOR TENSION HEADACHE RELIEF

Myofascial release is a manual thrust applied to the body face to treat the facial system. Myofascial release restores the flexibility and elasticity of the fascia, thus having a broad ability to alter the body's range of motion and dissolve restrictions in the fascial tissues. Sedentary lifestyle and positions that cause pain can gradually cause muscle and fascial restrictions and shortening. This study aims to identify the effectiveness of myofascial release in the cervical region for tension headache relief. This study is characterized as a bibliographical research of qualitative descriptive character, where the researcher is the one who describes the research object, assuming the role of observer and explorer, directly collecting the data in the place where the study phenomena occurred or appeared. It is concluded that through the use of this technique, it is possible to deactivate trigger points, promote a correct alignment of the body structure, minimize movement restriction and pain without compromising the myofascial structures.

Anterior Cervical Surgery for the Treatment of Cervicogenic Headache Caused by Cervical Spondylosis.

Study DesignRetrospective study.ObjectiveTo report the efficacy of anterior cervical surgery for the relief of cervicogenic headache (CEH) caused by cervical spondylosis.MethodsFrom January 2014 to December 2016, a total of 166 cases of cervical radiculopathy and/or myelopathy received anterior cervical decompression and fusion (ACDF) in our institution, among which 50 cases (mean age 44.7 years) were accompanied by CEH and followed up at 3, 6, 12, and 24 months postoperatively, respectively. Neck pain and headache scores according to neck disability index (NDI) were documented for all patients at regular intervals. The results measured at different follow-up time point were compared statistically.ResultsAll 50 patients reported neck pain and headache at the same time before surgery. The average NDIs for neck pain before and after surgery were 2.86 (95% CI: 2.7–3.0) preoperatively, 0.98 (95% CI: 0.8–1.1) at 3 months, 0.68 (95% CI: 0.5–0.9) at 6 months, 0.62 (95% CI: 0.5–0.8) at 12 months, and 0.60 (95% CI: 0.4–0.8) at 24 months postoperatively, respectively. The average NDIs for CEH before and after surgery were 2.32 (95% CI: 2.2–2.5) preoperatively, 0.62 (95% CI: 0.5–0.8) at 3 months, 0.60 (95% CI: 0.4–0.8) at 6 months, 0.56 (95% CI: 0.4–0.7) at 12 months, and 0.50 (95% CI: 0.3–0.7) at 24 months postoperatively, respectively. The neck pain and headache improved in all cases and the NDI score of neck pain or headache at each follow-up point after surgery was significantly different from that before surgery (P <0.001). The simple correlation analysis between neck pain and headache was performed, and the Pearson coefficient r was 0.71, indicating a positive correlation between neck pain NDI and headache NDI. No serious surgical complications were found.ConclusionOur study suggests that patients with cervical spondylosis complicated with CEH are always accompanied by neck pain. ACDF can not only relieve neck pain but also improve the accompanying CEH.

Migraine Treatment in Emergency Departments of Brazil: A Retrospective Study of 2 Regions.

This study describes the approaches, medications used, and time of care for migraineurs, who have been in emergency departments (ED) from 2 different regions of Brazil. Retrospective, cross-sectional, observational, non-randomized study of migraine patients seen at 2 headache centers in Brazil. Eighty-four migraine patients (15 men and 69 women) were divided into 2 groups: chronic (19%, n=16) and episodic migraineurs (81%, n=68). In the ED, medications were used in the following order of frequency: dipyrone or metamizole (89.3%, 75/84), nonsteroidal anti-inflammatory drugs (57.1%; 48/84) opioids (51.1%; 43/84), metoclopramide (29.8%; 25/84), dexamethasone (28.6%; 24/84), chlorpromazine (13.1%; 11/84), and subcutaneous sumatriptan (7.1%; 6/84). The average time in the care center was 8.2hours, but only 23 patients (27.4%) left the hospital with greater than 50% relief in headache severity. Dipyrone and nonsteroidal anti-inflammatories were the most used drugs, but nearly half received opioids. More efficient drugs were poorly used. Considering the number of patients leaving the hospital with headache relief, a changing treatment paradigm should be carried out in Brazil.

The Relevance View: Defended and Extended

AbstractThe Relevance View, exemplified by Alex Voorhoeve's Aggregate Relevant Claims, has considerable appeal. It accommodates our reluctance to aggregate weak claims in canonical cases like Life for Headaches (where one person's claim to life-saving treatment competes with millions of claims for headache relief), while permitting aggregation of claims in a range of other cases. But it has been the target of significant criticism. In an important recent paper, Patrick Tomlin argues that the view suffers from failures of internal logic, violating plausible consistency constraints and generating incoherent combinations of verdicts on cases. And in cases resembling real-world healthcare allocation problems, Tomlin argues that the view offers no guidance at all. In response, I argue that the internal logic of the Relevance View is sound, and the view's core principles, suitably clarified, support a significant extension of the view beyond the simple cases to which it is typically applied.

108 A Randomized, Placebo-Controlled Study of Metoclopramide + Diphenhydramine for Acute Post-Traumatic Headache

We conducted a randomized, placebo-controlled study to determine whether intravenous metoclopramide 20mg IV + diphenhydramine 25mg (M+D) was efficacious for acute moderate or severe post-traumatic headache. This was a double-blind study conducted in two emergency departments. The primary outcome was improvement in pain on a 0-10 scale between time 0 and one hour later. Secondary outcomes were sustained headache relief for 48 hours and score on a 22-item post-concussive symptom scale, on which higher scores indicate more severe symptomotology. 416 patients were screened for participation and 160 were randomized, 81 to M+D and 79 to placebo. Baseline characteristics were comparable between the groups. By one hour, placebo patients reported mean improvement of 3.8 (SD 2.6) while M+D improved by 5.2 (SD 2.3). The 95% CI for difference of 1.4: 0.7, 2.2. Sustained headache relief was reported by 18/76 (24%) placebo patients and 24/78 (31%) M+D patients (95% CI for 7% difference -7, 21%. One week after the ED visit, the mean PCSS score in the M+D group was 14, and 21 in placebo (95% CI for difference of 7: 0, 15). M+D was more efficacious than placebo with regard to relief of post-traumatic headache in the ED though this benefit was not sustained beyond the ED visit. Patients who received MCP reported fewer post-concussive symptoms one week later.

A Randomized, Double‐Dummy, Emergency Department‐Based Study of Greater Occipital Nerve Block With Bupivacaine vs Intravenous Metoclopramide for Treatment of Migraine

Greater occipital nerve blocks (GONB) are used increasingly to treat acute migraine. We conducted a randomized controlled trial to determine whether GONB was as effective as intravenous metoclopramide for migraine. This was a double-dummy, double-blind, parallel-arm, non-inferiority study conducted in 2 emergency departments (EDs). Patients with migraine of moderate or severe intensity were randomized to receive bilateral GONB with each side administered 3mL of bupivacaine 0.5% or metoclopramide 10mg IV, the putative standard of care. The primary outcome was improvement in pain on a 0-10 scale between time 0 and 1hour later. To reject the null hypothesis that metoclopramide would be more efficacious in relieving pain, we required that the lower limit of the 95% CI for the difference in pain improvement between those randomized to GONB vs those randomized to metoclopramide be >-1.3, a validated minimum clinically important difference. Secondary outcomes included sustained headache relief, defined as achieving and maintaining for 48hours a headache level of mild or none without the use of additional analgesic medication, and the use of rescue medication in the ED. Over a 2.5-year study period, 1358 patients were screened for participation and 99 were randomized, 51 to GONB and 48 to metoclopramide. All of these patients were included in the primary analysis. Patients who received the GONB reported mean improvement of 5.0 (95% CI: 4.1, 5.8) while those who received metoclopramide reported a larger mean improvement of 6.1 (95% CI: 5.2, 6.9). The 95% CI for the between group difference of -1.1 was -2.3, 0.1. Sustained headache relief was reported by 11/51 (22%) GONB and 18/47 (38%) metoclopramide patients (95% CI for rounded difference of 17%: -1, 35%). Of the 51 GONB patients, 17 (33%) required rescue medication in the ED vs 8/48 (17%) metoclopramide patients (95% CI for rounded difference of 17%: 0, 33%). An adverse event was reported by 16/51 (31%) GONB patients and 18/48 (38%) metoclopramide patients (95% CI for (rounded) difference of 6%: -13, 25%). GONB with bupivacaine was not as efficacious as IV metoclopramide for the first-line treatment of migraine in the ED.

Headache and rhinosinusitis: A review.

To explain our current understanding of headache attributed to rhinosinusitis, an often inappropriately diagnosed secondary headache. Recent studies have shown that headache attributed to rhinosinusitis is often over-diagnosed in patients who actually have primary headache disorders, most commonly migraine. Failure to recognize and treat rhinosinusitis, however, can have devastating consequences. Abnormalities of the sinuses may also be treatable by surgical means, which may provide headache relief in appropriately selected patients. It is important for the practicing physician to understand how rhinosinusitis fits into the differential diagnosis of headache, both to avoid overdiagnosis in patients with primary headache, and to avoid underdiagnosis in patients with serious sinus disease.

PARACETAMOL, MIGRAINE, AND MEDICATION OVERUSE HEADACHE (MOH)

Paracetamol is a nonopioid synthesized p-aminophenol derivative that used as an antipyretic and an analgesic. Paracetamol is an over the counter medicine. 15.6% of migraine patients took paracetamol for headache relief. In migraine, paracetamol is used long term. This triggers paracetamol to cause Medication Overuse Headache (MOH). Animal studies associated paracetamol induced MOH based on pathophysiology migrenes. There three mechanism underline MOH include effect to korteks cerebral, effect to system trigeminal nociception, and effect to central modulating systems.

Headaches and Magnesium: Mechanisms, Bioavailability, Therapeutic Efficacy and Potential Advantage of Magnesium Pidolate.

Magnesium deficiency may occur for several reasons, such as inadequate intake or increased gastrointestinal or renal loss. A large body of literature suggests a relationship between magnesium deficiency and mild and moderate tension-type headaches and migraines. A number of double-blind randomized placebo-controlled trials have shown that magnesium is efficacious in relieving headaches and have led to the recommendation of oral magnesium for headache relief in several national and international guidelines. Among several magnesium salts available to treat magnesium deficiency, magnesium pidolate may have high bioavailability and good penetration at the intracellular level. Here, we discuss the cellular and molecular effects of magnesium deficiency in the brain and the clinical evidence supporting the use of magnesium for the treatment of headaches and migraines.

Drug-induced headache: an analysis of therapeutic strategies

To manage patients with drug-induced headache (DIH) is an unsolved problem of modern neurology in developed countries, since DIH is becoming a common cause of temporary disability and leads to lower quality of life in patients. Patients with primary headache (for example, those with tension headache or migraine) frequently take symptomatic headache relief medications uncontrollably, which can result in the higher frequency and intensity of DIH episodes. In turn, new headache attacks make the patients take the increasing number of symptomatic medications, which leads to the development of DIH.The International Classification of Headache Disorders, 3 rd Edition, defines DIH as a distinct form of secondary headache. To date, there is no consensus on the tactics of DIH treatment and prevention. The paper discusses different approaches to DIH prevention and treatment, the effectiveness and appropriateness of their use, as well as factors influencing illness course and possible outcomes. Particular attention is paid to the management of patients during the withdrawal period, risk factors for DIH recurrences, and ways of their prevention.

Intravenous sodium valproate for acute migraine in the emergency department: A meta‐analysis

The role of intravenous sodium valproate (iVPA) in acute migraine attack has not been completely established. The aim of this updated review was to evaluate the efficacy and safety of iVPA in patients with acute migraine in the emergency department. We searched the PubMed, Web of Science, and Cochrane Library databases for relevant randomized controlled trials (RCTs). The primary outcome was improvement of headache intensity and headache relief. The need for rescue therapy, recurrence of headache, and number of adverse events was also assessed. Seven double-blinded RCTs involving 682 patients were analyzed. Overall, patients receiving iVPA had less improvement of headache intensity (SMD: -0.39, 95% CI: -0.73 to -0.06, P=.02) and lower rate of headache relief (OR: 0.51, 95% CI: 0.33 to 0.77, P=.002) than those receiving other active comparators. In addition, iVPA increased the odds of rescue therapy compared with other active drugs (OR: 3.76; 95% CI: 1.96 to 7.20, P<.0001). Subgroup analysis showed that iVPA was comparable to dexamethasone, with similar improvement of headache intensity, and recurrence of headache. For migraine without aura, we found no significant difference in headache intensity improvement when iVPA was compared with active comparators (SMD: -0.00, 95% CI: -0.54 to 0.54, P=1.00). iVPA was inferior to the studied comparators and was comparable to dexamethasone for aborting migraine attack. Based on the available evidence, iVPA may be a reasonable alternative or salvage therapy. In particular, iVPA might be a promising agent for migraine with aura and migraine status.

Medication Overuse Withdrawal in Children and Adolescents Does Not Always Improve Headache: A Cross-Sectional Study.

Background: MOH can be diagnosed in subjects with headache occurring 15 days/month in association with a regular medication overuse, but its existence is not universally accepted. ICHD-3 redefined criteria for MOH, removing the criterion associating drug suspension with headache course. The aim of our study was to compare the rate of patients diagnosed with medication overuse headache (MOH) according to ICHD-2 and ICHD-3 criteria, to verify the degree of concordance. The secondary aim was to verify if drug withdrawal was really associated with pain relief.Methods: In this cross-sectional study, we retrospectively analyzed a sample of 400 patients followed for primary chronic headache at the Headache Center of Bambino Gesù Children's Hospital. We then selected those presenting with a history of medication overuse, and we applied both ICHD-2 and ICHD-3 criteria to verify in which patients the criteria would identify a clinical diagnosis of MOH.Results: We identified 42 subjects (10.5%) with MOH; 23 of them (55%) presented a relief of headache withdrawing drug overuse. Regarding the applicability of the ICHD-2 criteria, 43% of patients (18/42) fulfilled all criteria, while all ICHD-3 diagnostic criteria were satisfied in 76% of patients (32/42). Eighteen patients (43%) satisfied both ICHD-2 and ICHD-3 criteria, while 10 patients (24%) did not satisfy either diagnostic criterion.Conclusions: Our study suggests that in children and adolescents, withdrawing medication overuse is not always associated with a clinical benefit. Therefore, though allowing a MOH diagnosis in a higher rate of patients as compared to ICHD-2, the application of ICHD-3 criteria does not guarantee a true a causal relationship between medication overuse and headache worsening.

Pain freedom after 2 hours should be the primary outcome in controlled trials treating migraine attacks.

Pain freedom after 2 hours is the recommended primary endpoint by the International Headache Society in randomized trials investigating drug treatment of acute migraine attacks. In order to demonstrate an early effect of a drug, some drug companies, however, have promoted headache relief (improvement from severe or moderate pain to mild or no pain) at earlier time points than 2 hours as outcome parameter. We analyzed the relationship between pain freedom and headache relief in acute migraine trials and observed that persistent mild headache constituted 90% of headache relief after 0.5 hour and 40% of headache relief after 2 hours. Headache relief at 2 hours should in our view only be used as an outcome measure for comparison with historic data. Prior to 2 hours, headache relief varies with time from intake and the therapeutic gain is very small. Therefore, pain freedom should be used at these early time points.

Headache Relief Is Maintained 7 Years After Anterior Cervical Spine Surgery: Post Hoc Analysis From a Multicenter Randomized Clinical Trial and Cervicogenic Headache Hypothesis.

ObjectiveTo evaluate whether anterior cervical spine surgery offers sustained (7 years) relief in patients with cervicogenic headaches (CGHs), and evaluate the difference between cervical disc arthroplasty (CDA) and anterior cervical discectomy and fusion (ACDF) for 1 and 2-level surgeries from a multicenter randomized clinical trial. MethodsA post hoc analysis was performed of 575 patients who underwent one or 2-level CDA or ACDF for symptomatic cervical spondylosis as part of a prospective randomized clinical trial. Assessment of pain and functional outcome was done with the Neck Disability Index (NDI) in the trial. We used the NDI headache component to assess headache outcome. ResultsFor both 1- and 2-level CDA and ACDF groups, there was significant headache improvement from preoperative baseline out to 7 years (p < 0.0001). For 1-level surgeries, headache improvement was similar for both groups at the 7-year point. For 2-level treatment, CDA patients had significantly improved headache scores versus ACDF patients at the 7-year point (p = 0.016). ConclusionThe headache improvement noted at early follow-up was sustained over the long-term period with ACDF and CDA populations. In the case of 2-level operations, CDA patients demonstrated significantly greater benefit compared to ACDF patients over the long-term. Sinuvertebral nerve irritation at the unco-vasculo-radicular junction and anterior dura may be the cause of CGH. Therefore, it is possible that improved cervical kinematics and preservation of range of motion at adjacent uncovertebral joints in CDA may contribute to the observed difference between the groups.

Determinants and effects of self-administration with NSAIDs in a tertiary care hospital of Eastern India

Introduction: Self-Medication is a practice common in developing countries, and accepted in society, unlike the western world. NSAIDs are responsible for the delayed diagnosis (due to suppression of clinical features), disease progression and adverse effects. Objective: To determine the factors leading to self-administration of NSAIDs, their usage pattern and possible adverse effects. To compare NSAID’s use by prescription and over the counter acquisition. Materials and Methods: The present study investigates the determinants and effects of self-administration of NSAIDs by patients attending a tertiary care hospital during August- October 2019. The patients were interviewed regarding basic socio demographic variables, their rationale behind taking NSAIDs along with adverse effects experienced by them with a validated questionnaire. Their awareness pertaining to the drugs was also assessed. Results: 55.2% of the population were aware about adverse drug reaction due to NSAIDs but only 17% suffered any consequence of such activity. 23% of the patients were not aware about the nature of the disease whereas 44.2% visited physician less than 1 month. Awareness regarding adverse drug reaction is more in elderly and middle aged in compare to youth. The intention to administer the drugs was relief of musculoskeletal pain (62.9%) followed by relief of headache (15.2%) followed by others. The people at the medicine shops are advisors to majority of the people administering drugs without prescription (42.9%) followed by family members (32.4%), colleagues as well as friends. Conclusion: We found large proportion of patients taking self-prescribed NSAIDs for symptomatic relief and advice by overenthusiastic peers. Keywords: NSAIDs, Self-medication, Over the counter, Patients, ADR.

In-Vitro Comparative Dissolution Study of Commercially Available Paracetamol Tablet

Quality is the most important issue in the pharmaceutical field due to the presence of a drug which is considered as safe and therapeutically active agent. In-vitro evaluation ensures their quality, bioavailability as well as optimum therapeutic activity. Paracetamol (acetaminophen) which are the active metabolites of phenacetin is commonly used for the relief of headaches and pains, and is a major ingredient in numerous cold and flu remedies. Paracetamols are available in different brands in Indian market. The main objective of the present study was to conduct the comparative in-vitro dissolution studies of various brands collected from the local market to determine whether all the formulations used were equivalent or significantly different. The calibration curve was constructed covering the concentration range of 1 to 10 mcg/ml at 268 nm by UV spectrophotometer (UV 2203 Double beam spectrophotometer, Shimadzu). Five different brands of Paracetamol of 500 mg conventional tablets from different manufacturers were selected in the study and dissolution testing in Phosphate buffer at pH 7.4 was conducted from each brands for 90 mins by using dissolution testing apparatus USP type-II. The dissolution rate was subjected to various mathematical models like zero order, first order, Higuchi and Hixson-Crowell equations to elucidate the kinetic behavior of drug release from the test samples. Different release kinetics model of all the selected brands was assuring the quality standard of manufacturing.&#x0D; Keywords: Paracetamol, Marketed Tablet, In-Vitro dissolution study, Release profile.